Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Puma Aims To File Nerlynx In Third-line HER2-positive Breast Cancer By July

Executive Summary

Puma's CEO voiced confidence the biotech's lead asset Nerlynx will be approved in third-line HER2-positive metastatic breast cancer after its Phase III NALA study met co-primary endpoints.

You may also be interested in...



Freshly Funded ImCheck Goes After Gamma Delta T-Cells

ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.

Novartis Enters ‘Transformational’ Cloud Computing Pact With Amazon

Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.

Macrophage Pharma Seeks Funding To Take Novel Cancer Therapy Forward

Macrophage Pharma’s lead asset will advance to clinical trials next year, making a series B financing round necessary, the UK biotech’s CEO tells Scrip.  

Topics

Related Companies

UsernamePublicRestriction

Register

SC124385

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel